6-Aminohexanoic Acid vs Tranexamic Acid: A Sourcing Comparison

23-07-2026

Quick answer: 6-Aminohexanoic acid (EACA) and tranexamic acid are both synthetic lysine analogues that inhibit fibrinolysis, but tranexamic acid is a cyclic structure generally considered more potent per milligram, while 6-Aminohexanoic acid is a simpler straight-chain molecule with broader industrial uses (nylon-6 production, peptide synthesis) alongside its pharmaceutical role. From a sourcing standpoint, 6-Aminohexanoic acid requires more careful grade verification since industrial-grade and pharma-grade material both circulate under the same chemical name.

Formulators working on antifibrinolytic products often compare 6-Aminohexanoic acid (e-aminocaproic acid, EACA) against tranexamic acid, since both are lysine analogues used to inhibit fibrinolysis and both appear across similar dosage forms. While the clinical decision between them belongs to drug developers and regulatory bodies, procurement teams frequently need to understand how they differ as raw materials potency, dosage form fit, industrial crossover, and sourcing complexity all factor into how each is procured.

Structural relationship

Both compounds are synthetic derivatives related structurally to the amino acid lysine, and both work by a similar general mechanism blocking the conversion of plasminogen to plasmin, which slows the enzymatic breakdown of blood clots. The key structural difference is that 6-Aminohexanoic acid is the simpler, straight-chain (open-chain) molecule, while tranexamic acid is a cyclic analogue built around a cyclohexane ring structure.

This structural difference has downstream consequences for potency: tranexamic acid is generally considered more potent on a per-milligram basis than 6-Aminohexanoic acid, which is one reason dosage forms and product strengths differ between finished products built on each raw material. From a formulation science perspective, this also means the two compounds aren't simply substitutable at equivalent doses a reformulation from one to the other isn't a straightforward swap.

Typical dosage forms in the market

Both compounds appear across oral tablets, oral solutions, and injectable formulations, though exact product strengths and formulation approaches vary by manufacturer, market, and regulatory approval. Buyers sourcing raw material should always confirm with their formulation or regulatory affairs team which compound the finished product specification calls for the two compounds are related in mechanism but not interchangeable at the same dose or necessarily approved for the same indications in every market.

Sourcing considerations: a side-by-side comparison

Factor	6-Aminohexanoic acid	Tranexamic acid
Structural class	Straight-chain (open-chain) lysine analogue	Cyclic lysine analogue
Relative potency	Lower per milligram	Generally higher per milligram
Other industrial uses	Nylon-6 precursor, peptide synthesis linker	Primarily pharmaceutical use
Grade differentiation needed	Yes — industrial vs pharma grade both exist under the same name	Less common outside pharma grade
Monograph coverage	USP, EP, JP	USP, EP, JP
Typical buyer confusion point	Confirming pharma-grade vs industrial-grade material	Less common, since demand is concentrated in pharma

Why 6-Aminohexanoic acid needs more careful grade verification

Because 6-Aminohexanoic acid has meaningful non-pharmaceutical demand particularly from nylon-6 fiber manufacturing and from peptide synthesis research buyers should be more careful to confirm they're being quoted pharmacopoeial-grade material specifically, rather than industrial-grade product sold under the same chemical name at a lower price point.

Tranexamic acid, by comparison, has a supply chain more concentrated around pharmaceutical use, which generally means less ambiguity when a supplier quotes "tranexamic acid" without further grade specification. This doesn't mean tranexamic acid buyers can skip due diligence entirely monograph compliance still needs to be confirmed but the risk of an unintentional grade mismatch is structurally lower.

Regulatory and documentation parallels

Both compounds are referenced across USP, EP, and JP monographs, and buyers sourcing either for a regulated-market filing should request the same core documentation package: batch-specific Certificate of Analysis, impurity profile, heavy metals data, and where applicable DMF or CEP references supporting the specific manufacturing source. The documentation expectations don't differ meaningfully between the two compounds; what differs is the additional grade-verification step that 6-Aminohexanoic acid buyers need to build into their sourcing process.

What this means for procurement teams

If your formulation is already specified around one compound, this comparison is mostly academic you'll source what your regulatory filing requires, and the choice between the two was made earlier in development, not at the procurement stage. But for teams still evaluating raw material options at the development or reformulation stage, understanding that 6-Aminohexanoic acid has a broader industrial supply chain and therefore more grade variability to check for is a genuinely useful sourcing consideration that tranexamic acid buyers don't face in quite the same way.

This is also a useful factor when comparing supplier quotes: if one quote for 6-Aminohexanoic acid comes in notably cheaper than others, it's worth double-checking whether the lower price reflects industrial-grade material rather than pharmacopoeial-grade a mismatch that's easy to catch early but harder to catch after the material has already arrived.

Frequently asked questions

Are 6-Aminohexanoic acid and tranexamic acid interchangeable in formulations?

No. They differ in potency and structure, and switching between them in a formulation is a reformulation decision requiring its own development and regulatory work not a simple raw material substitution.

Which one is more widely used in pharmaceutical manufacturing?

Both are established antifibrinolytic raw materials with long histories of pharmaceutical use; the choice between them for a given product depends on the original formulation and regulatory approval, not on general market preference.

Why does 6-Aminohexanoic acid need more grade verification than tranexamic acid?

Because 6-Aminohexanoic acid also serves as a raw material for nylon-6 polymer production and as a peptide synthesis linker, industrial-grade and pharma-grade material both circulate under the same chemical name. Tranexamic acid's demand is more concentrated in pharmaceutical use, reducing this particular sourcing risk.

Do both compounds require the same storage conditions?

Both are moisture-sensitive amino acid derivatives and generally require similar controlled storage conditions, though buyers should confirm specific stability data from their supplier for each compound rather than assuming identical handling requirements.

The bottom line

6-Aminohexanoic acid and tranexamic acid share a mechanism and a general therapeutic category, but they differ meaningfully in structure, potency, and critically for procurement teams in how much grade verification is needed at the sourcing stage. Buyers evaluating either compound should request monograph-specific documentation as standard practice, and for 6-Aminohexanoic acid in particular, should treat "grade confirmation" as a non-negotiable step given its broader industrial supply chain.

Sourcing pharmacopoeial-grade antifibrinolytic raw materials? Compare 6-Aminohexanoic acid options on Clyzo with monograph-verified specifications and batch-specific documentation.

Vaccine Excipients Oral Topical Biopharma

Ethanol 96% v/v for pharmaceutical excipients (Ph.... ... Ethanol 96% v/v for pharmaceutical excipients (Ph.Eur., BP, USP IPEC Grade) | Clyzo Read more

14-08-2026